CELL INTELLIGENCE · 肿瘤细胞治疗研究

免疫效应细胞相关肠炎的组织学谱系与 T 细胞克隆性特征

Characterization of Histologic Spectrum and T-Cell Clonality in Immune Effector Cell-Associated Enteritis.

Idecabtagene Vicleucel 后 100 天内的感染及其对复发/难治性多发性骨髓瘤生存的影响：一项 CIBMTR 分析

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

将 B 细胞与浆细胞靶向从肿瘤学转化至自身免疫：模式、定量桥接与开发路线图

Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap.

CAR 疗法在肿瘤与自身免疫领域的演进：机制见解与治疗创新

The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations.

CAR-T 细胞治疗临床试验全景与发展趋势的全球多维分析

A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends.

多发性骨髓瘤与拟态：CAR-T 细胞治疗和抗 CD38 单克隆抗体治疗后患者的胃肠道组织学表现

Multiple Myeloma and Mimicry: Gastrointestinal Tract Histologic Findings in Patients Following Chimeric Antigen Receptor T-cell Therapy and Anti-CD38

针对 Dickkopf-1-A2 复合物工程化的 T 细胞可用于治疗 HLA-A2(+) 实体瘤和血液系统肿瘤

T cells engineered against Dickkopf-1-A2 complex can be used to treat HLA-A2(+) solid and hematologic cancers.

SOHO 最新进展与后续问题 | 高级别 B 细胞淋巴瘤的诊断与治疗

SOHO State of the Art Updates and Next Questions | Diagnosis and Management of High-Grade B-Cell Lymphomas.

血液系统恶性肿瘤中 CD19 靶向 CAR-T 细胞治疗后的皮肤不良事件

Dermatologic Adverse Events Following CD19-Directed CAR T-Cell Therapy in Hematologic Malignancies.

CAR-T 细胞治疗后的 dAEs 常见，但多为低级别，且通常在输注后第 1 个月内出现。

氟达拉滨清淋暴露与复发/难治性多发性骨髓瘤患者接受 Idecabtagene-Vicleucel 后毒性相关：来自美国骨髓瘤免疫治疗联盟的真实世界经验

Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Ex

在该真实世界中接受 ide-cel 治疗的人群中，预测的 Flu 暴露是 CAR-T 毒性的独立预测因素。